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Abstract
The kallikrein-kinin and renin-angiotensin systems interact at multiple levels. In the present study, we tested the hypothesis
that the B1 kinin receptor (B1R) contributes to vascular hypertrophy in angiotensin II (ANG II)–induced hypertension,
through a mechanism involving reactive oxygen species (ROS) generation and extracellular signal-regulated kinase (ERK1/2)
activation. Male Wistar rats were infused with vehicle (control rats), 400 ng/Kg/min ANG II (ANG II rats) or 400 ng/Kg/min
ANG II plus B1 receptor antagonist, 350 ng/Kg/min des-Arg9-Leu8-bradykinin (ANGII+DAL rats), via osmotic mini-pumps (14
days) or received ANG II plus losartan (10 mg/Kg, 14 days, gavage - ANG II+LOS rats). After 14 days, ANG II rats exhibited
increased systolic arterial pressure [(mmHg) 18465.9 vs 11562.3], aortic hypertrophy; increased ROS generation [2-
hydroxyethidium/dihydroethidium (EOH/DHE): 21.862.7 vs 6.061.8] and ERK1/2 phosphorylation (% of control: 218.3629.4
vs 10060.25]. B1R expression was increased in aortas from ANG II and ANG II+DAL rats than in aortas from the ANG II+LOS
and control groups. B1R antagonism reduced aorta hypertrophy, prevented ROS generation (EOH/DHE: 9.1763.1) and ERK1/
2 phosphorylation (137620.7%) in ANG II rats. Cultured aortic vascular smooth muscle cells (VSMC) stimulated with low
concentrations (0.1 nM) of ANG II plus B1R agonist exhibited increased ROS generation, ERK1/2 phosphorylation,
proliferating-cell nuclear antigen expression and [H3]leucine incorporation. At this concentration, neither ANG II nor the B1R
agonist produced any effects when tested individually. The ANG II/B1R agonist synergism was inhibited by losartan (AT1
blocker, 10 mM), B1R antagonist (10 mM) and Tiron (superoxide anion scavenger, 10 mM). These data suggest that B1R
activation contributes to ANG II-induced aortic hypertrophy. This is associated with activation of redox-regulated ERK1/2
pathway that controls aortic smooth muscle cells growth. Our findings highlight an important cross-talk between the DABK
and ANG II in the vascular system and contribute to a better understanding of the mechanisms involved in vascular
remodeling in hypertension.
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Introduction
The kallikrein-kinin (KKS) and renin-angiotensin (RAS) systems
play a key role in multiple physiological and pathophysiological
conditions, including blood pressure regulation, vascular smooth
muscle cells (VSMC) growth, and inflammation. The KKS and
RAS systems also interact at multiple levels, therefore, changes in
the activity of one system greatly impact the activity of the other
[1].
Angiotensin II (ANG II) is the main RAS vasoactive peptide.
The cellular effects of ANG II are mediated by at least two
receptors subtypes, AT1 and AT2, which belong to the seven-
transmembrane G protein-coupled receptor (GPCR) superfamily
[2]. ANG II through AT1 receptor plays a key role in blood
pressure homeostasis and VSMC proliferation [3].
Kinin B1 (B1R) and B2 (B2R) receptors are GPCRs, which
mediate kinins effects. B2R is expressed constitutively and induces
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e111117
the classical effects of the nonapeptide hormone bradykinin, which
is one of the KKS effectors [4]. B1R mediates the actions of des-
Arg9-bradykinin (DABK), a metabolite of bradykinin. B1R is
weakly expressed in healthy tissues, but its expression is enhanced
during tissue injury, by proinflammatory cytokines or by growth
factors [4].
Originally described as an important regulator of inflammatory
processes [5], the function of B1R upregulated in the cardiovas-
cular system is not completely understood. It has been described
that B1R contributes to the protective effect of angiotensin
converting enzyme inhibitors in mice after myocardial infarction
[6]. On the other hand, the B1R upregulation has also been
associated with hypertension [7] and the development of vascular
diseases, such as atherosclerosis [8,9].
VSMC growth is a prominent feature of the vascular disease
process and it is associated with activation of a number of signaling
molecules, including mitogen-activated protein kinase (MAPK)
[10]. Intriguingly, DABK, B1R agonist, potentially stimulates
MAPK activity in cultured VSMC [7], and it is possible that one
of the vascular functions of B1R is to induce VSMC growth [9].
Hypertension is an important and potent risk factor for the
development of vascular disease. We demonstrated, in different
models of hypertension, that B1R expression is increased in the
vascular tissue of hypertensive animals [11,12]. This positive
modulation of B1R expression is dependent on ANG II/AT1
receptor, involves reactive oxygen species (ROS) generation and
nuclear translocation of nuclear factor kappa-B (NF-kB) [11,12].
However, the role of B1R in vascular hypertrophy in hypertension
is not clear. Therefore, we determined the functional role of B1R
in vascular hypertrophy associated with ANG II-dependent
hypertension. We also sought to understand the molecular
mechanisms underlying the crosstalk between ANG II and B1R
activation in VSMC, focusing on signaling events involving ROS
generation and MAPK activation.
Materials and Methods
Animals
Experiments were performed in male Wistar rats (n = 36)
weighing 180–200 g, obtained from the breeding stock of the
Institute of Biomedical Sciences of the University of Sao Paulo
(ICB-USP). Rats were kept in a temperature-controlled room on a
12-hour light/dark cycle, 60% humidity, standard rat chow and
water ad libitum. All the procedures used in this study were
approved and performed in accordance with the guidelines of the
Animal Ethics Committee of the ICB-USP (Permit Number: 145,
page 95, book 02), following the Guidelines for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
Induction of hypertension, B1R and AT1 antagonism
The induction of hypertension with ANG II was performed as
previously described [12]. Briefly, rats were anesthetized with
xylazine (7.4 mg/Kg, ip) and ketamine (113 mg/Kg, ip) and
osmotic minipumps (Alzet 2002) containing either ANG II
400 ng/Kg/min (ANG II group, n= 11) or saline 0.9% (control
group, n = 11) were subcutaneously implanted in the animals. In
another group, the des-Arg9-Leu8-bradykinin, a selective B1R
antagonist [13,14], was simultaneously infused with ANG II (ANG
II + DAL group, n= 10). The B1R antagonist was infused
subcutaneously by osmotic minipumps at a rate of 350 ng/Kg/
min. All infusions were performed for 14 days [15]. In another
series of experiments, ANG II infused-rats, were simultaneously
treated with losartan (10 mg/kg by gavage for 14 days; ANG II+
LOS; n= 5). Systolic arterial pressure was measured in conscious
rats by tail-cuff plethysmography (PowerLab 4/S, AD Instruments
Pty Ltd) at zero, 7, and 14 days after the minipump implantation,
as previously described [12] and calculated as the average of three
consecutive measurements.
Real-time PCR
The mRNA expression of B1 and AT1 receptors was
determined by real-time PCR, as previously described [11]. On
the 14th day after minipump implantation, the rats were
anesthetized with xylazine (7.4 mg/Kg, ip) and ketamine
(113 mg/Kg, ip), the thorax was opened and the descending
aorta was excised. Total cellular RNA was isolated from the aorta
using Trizol Reagent. Total RNA (2 mg) was used for first-strand
cDNA synthesis using SuperScript II. cDNA samples were
submitted to real-time PCR amplification using Platinum SYBR
QPCR Supermix-UDG and specific oligonucleotides (Invitrogen
Co., San Diego, CA) for: B1R (forward-GCATCCCCACATTCC
TTC TA; reverse-AAGAAGTGGTAAGGGCACCA); AT1 re-
ceptor (forward-CACTTTCCTGGATGTGCTGA; reverse-
CCCAGAAAGCCGTAGAACAG), and b-actin (forward-AA-
GATTTGGCACCACACTTTCTACA; reverse-CGGTGAG-
CAGCACAGGGT) that was used as an internal control. Real-
time PCR reactions were performed, recorded, and analyzed using
the Corbett Research system (Corbett Life Sciences, Sydney,
Australia). Expression data were calculated from the cycle
threshold (Ct) value using the DDCt method for quantification.
The expression of b-actin mRNA was used for normalization and
values expressed as fold of control.
Morphological analysis
For the analysis of vascular hypertrophy, animals were perfused
in fixed pressure with 4% sodium phosphate-buffered paraformal-
dehyde (4% PFA). The aorta was then removed and fixed in 4%
PFA, embedded in paraffin and cut into transversal sections
(4 mm). Samples were stained with hematoxylin-eosin. In the
morphological analysis, the external (EL), internal (IL) elastic
lamina and external (ED) and internal (ID) diameters were
determined and the cross-sectional area (CSA=EL-IL), wall
thickness (d=ED-ID/2) and the ratio media/lumen (media/
lumen= d/Di) were calculated. Digital photomicrographs of aortic
sections were analyzed using KS300 software, with the wall
thickness defined as the distance between the outer and inner
elastic lamine. A single investigator unaware of the experimental
groups performed the analysis.
ROS detection in aorta
The ROS generation in aorta was evaluated by HPLC analysis
and transverse sections fluorescence analysis, both involving
dihydroethidine (DHE) oxidantion. The DHE oxidation yields at
least two fluorescent products, 2-hydroxyethidium (EOH), known to
be more specific for superoxide anion, and the less-specific product
ethidium (E). Both dihydroethidine fluorescent products bind to
DNA and can be detected by virtue of its red fluorescence [16]. The
analysis of ROS by HPLC was performed as described previously
[16,12]. Briefly, aorta segments,<10 mm in length, were incubated
in DHE (50 mmol/L) in the dark (37uC, 30 min). Aortic segments
were homogenized in liquid nitrogen with pestle, suspended in
acetonitrile, centrifuged, and the supernatants injected into a high-
performance liquid chromatography system. DHE and DHE-
derived products, such as 2-hydroxyethidium (EOH) and ethidium
derived from oxidation of DHE by superoxide anion and by other
reactive oxygen species, were determined using ultraviolet and
fluorescence detection, respectively. Thus, the DHE-derived
Angiotensin II and Kinin Vascular Interaction
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products were expressed as a ratio of EOH and E generation per
DHE consumed (initial DHE concentration minus remaining
DHE). To determine ROS generation in transverse aortic sections,
aortic segments were embedded in tissue freezing medium and
snap-frozen. 10 mm thick cryosections were incubated in a light-
protected and humidified chamber (37uC, 30 min) with DHE
5 mM. Fluorescent images were detected with a 585–590 nm long-
pass filter, under a microscope (Axioskop, Zeiss) with a x40 objective
lens coupled to a digital camera.
Aortic smooth muscle cell primary culture
In order to investigate the possible mechanism responsible for
the contribution of B1R activation in ANG II signaling, aortic
VSMC from Wistar rats were examined. The study was approved
by the Animal Ethics Committee of the University of Ottawa and
performed according to recommendations of the Canadian
Council for Animal Care. Adult male Wistar rats were killed by
decapitation. VSMC derived from aorta were isolated and
characterized as described in detail previously [17]. In brief, aorta
was cleaned of adipose and connective tissue, and VSMC were
dissociated by digestion of vascular arcades with enzymatic
solution (collagenase, elastase, soybean trypsin inhibitor and BSA
type I; 60 min, 37uC). The tissue was filtered and the cell
suspension centrifuged and re-suspended in Dulbecco Minimal
Essential Medium (DMEM) containing 10% fetal calf serum,
2 mM glutamine, 20 mM Hepes (pH 7.4) and antibiotics. Each
cultured cell line was initially prepared from aorta pooled from 10
rats. Cells were cultured until passage 3 before being frozen for
storage in liquid nitrogen, and once thawed did not undergo
repeated freeze-thaw cycles. Cells were cultured in DMEM,
supplemented with 10% fetal bovine serum. At least four different
primary cell cultures were used between passages 4 and 7 [17]. For
the experiments involving ANG II and B1R agonist interaction the
culture medium was replaced with serum-free medium for 24 h to
render the cells quiescent.
To characterize the effect of ANG II in B1R expression, cells
were stimulated with ANG II (100 nM) for 0, 2, 4, 6, 8, 10 and
24 h. The synergistic effect of ANG II and the B1R agonist DABK
was evaluated by stimulating cells either with ANG II and/or
DABK, at low (0.1 nM) and high (100 nM) concentrations, for 5
minutes. Low concentrations were those that alone did not
produce any effect on ERK1/2 phosphorylation and high
concentrations were those that individually induced nearly
maximal kinase phosphorylation [17,18]. The low and high
concentrations were determined by performing concentration-
effect curves (data not shown) and by previous studies from our
group [18]. This protocol was also performed in cells preexposed
for 30 minutes to: 10 mM losartan (LOS - selective AT1 receptor
antagonist), 10 mM des-Arg9-Leu8-bradykinin (DAL - selective
B1R antagonist) or 1 mM Tiron (superoxide anion scavenger).
Protein analysis by Western blot
Proteins were extracted from aorta and VSMC in culture,
separated by electrophoresis on a 10% polyacrylamide gel, and
transferred onto a nitrocellulose membrane, as previously
described [18]. Nonspecific binding sites were blocked with 5%
skim milk in Tris-buffered saline solution with Tween for 1 h at
24uC. Membranes were then incubated with phospho-specific
antibodies (1:1000) overnight at 4uC. Antibodies were incubated
with anti-extracellular signal-regulated kinase (ERK1/2) (Thr202/
Tyr204 - Cell Signaling). The ERK1/2 nonphosphoantibodies
(1:2000) were also used in the present study (Cell Signaling). In
other series of experiments membranes from VSMC were then
incubated with anti-B1R (1:1000) (Santa Cruz Biotechnology,
Santa Cruz, California, USA) or anti-proliferating-cell nuclear
antigen (PCNA) (Cell Signaling) and also anti-b-actin (Santa Cruz
Biotechnology, Santa Cruz, California, USA) at 4uC. b-actin was
used as a housekeeping protein. After incubation with secondary
antibodies, signals were revealed with chemiluminescence, visual-
ized by autoradiography, and quantified densitometrically. Results
were normalized by the total protein and expressed as percentage
of vehicle used in the experimental protocols for cells and control
aorta.
VSMC protein synthesis
The protein synthesis was quantified on the basis of tritiated
leucine incorporation [19]. VSMC were stimulated with ANG II
(0.1 nM) and the B1R agonist, DABK (0.1 nM) alone or in
association, for 24 hours. The same protocol was performed after
pre-exposing cells for 30 min to: 10 mM LOS and 10 mM DAL.
The VSMC were also stimulated with ANG II in high
concentration (100 nM) for 24. At 6 h before harvest, L-[3,4,5-
3H] leucine (5 mCi/ml) was added to the culture medium to
measure incorporation into newly synthesized protein. Total
cellular proteins were precipitated in ice-cold 10% trichloroacetic
acid and collected by centrifugation (14,000 g for 10 min at 4uC).
The proteins pellets were washed twice by re-suspension in cold
10% trichloroacetic acid and collected by centrifugation. The final
pellets were dissolved in 0.2 N NaOH by incubation at 60uC for
30 min. Radioactivity was measured by liquid scintillation
counting. Protein concentrations were determined with protein
assay reagent (Bio-Rad Laboratories). The [H3] leucine incorpo-
ration was normalized by the total protein and demonstrated as
percentage of control cells (vehicle).
Detection of superoxide anion in VSMC by lucigenin
chemiluminescence
The lucigenin-derived chemiluminescence assay was used to
determine superoxide anion generation [20]. VSMC were
stimulated with ANG II (0.1 nM) and the B1R agonist DABK
(0.1 nM) alone or in association, for 5 min. The same protocol was
performed after pre-exposing cells for 30 min to: 10 mM LOS,
10 mM DAL or 1 mM Tiron. In another series of experiments,
VSMC were stimulated with ANG II in high concentration
(100 nM), for 5 min, after being pre-exposed for 30 min to:
vehicle, 10 mM LOS or 10 mM DAL. Superoxide anion produc-
tion was measured by lucigenin-enhanced chemiluminescence.
The reaction was started by the addition of NADPH (0.1 mM) to
the suspension (250 ml of final volume) containing sample (50 ml),
lucigenin (5 mM) and assay buffer [50 mM of KH2PO4, 1 mM of
EGTA, and 150 mM of sucrose (pH 7.4)]. Luminescence was
measured every 1.8 s for 3 min in a luminometer (Orion
Luminometer, Berthold detection systems). Buffer blank was
subtracted from each reading. Superoxide anion production was
expressed as the percentage increase from baseline values. Protein
concentrations were determined with protein assay reagent (Bio-
Rad Laboratories).
Drugs and reagents
Angiotensin II and des-Arg9-Leu8-bradykinin were purchased
from Bachem Bioscience Inc. (Pensylvania, USA). Antibodies were
purchased from Santa Cruz Biotechnology or Cell Signaling
Technology (Beverly, USA).
Statistical analysis
Data are means 6 SEM of n samples. B1R and AT1 mRNA
levels were measured relative to b-actin mRNA levels. B1R and
Angiotensin II and Kinin Vascular Interaction
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PCNA protein levels were measured relative to b-actin protein. p-
ERK1/2 protein expression was normalized to total ERK1/2
levels. Statistical analysis was performed with GraphPad Prism
software. Results were analyzed by one-way ANOVA in
conjunction with a Bonferroni post-test for in vivo study or by
one-way ANOVA followed by Dunnett’s test for multiple
comparisons with control cells (vehicle). P,0.05 was considered
significant.
Results
ANG II increases B1R expression in aorta and in VSMC
ANG II infusion (400 ng/Kg/min) increased aortic B1R
mRNA expression in comparison with control. The B1R
antagonist did not interfere with the effects of ANG II on B1R
expression (Figure 1A). Treatment with LOS inhibited ANG II-
induced increased aortic B1R mRNA expression. Neither ANG II,
ANG II+DAL nor ANG II+LOS infusion altered AT1 receptor
mRNA vascular expression when compared to those in aortas of
control rats (Figure 1B). We also examined the effect of ANG II on
B1R protein expression in aortic VSMC at different time points.
As shown in Figure 1C, ANG II (100 nM) increased B1R
expression in a time-dependent manner, with a maximal increase
at 2 h that last for up to 6 h when compared to unstimulated cells.
B1R protein expression returned to basal levels at 8h post-ANG II
stimulation and remained up to 24 h. LOS incubation blunted
ANG II effects on B1R expression (Figure 1D).
Effect of B1R and AT1 antagonism on systolic arterial
pressure levels and aortic morphology
Table 1 summarizes the data on systolic arterial pressure levels
and aortic wall morphology. ANG II infusion for 14 days resulted
in a progressive increase in systolic arterial pressure in comparison
with the control group, measured at the 7th and 14th days.
Treatment with the B1R antagonist did not interfere with the
increase in systolic arterial pressure observed in ANG II-infused
rats. On the other hand, the AT1 receptor antagonist LOS
blunted ANG II-induced hypertension.
After 2-weeks of ANG II infusion (400 ng/Kg/min) the CSA
and wall thickness were increased approximately 40% and 31%,
respectively, when compared with control. B1R antagonism
reduced and AT1 receptor antagonism prevented the ANG II-
induced changes in CSA and wall thickness. There were no
differences in W/L ratio among the groups.
B1R antagonism reduces vascular ROS generation and
ERK1/2 phosphorylation in ANG II-infused rats
Aortic sections from ANG II-infused rats exhibited increased
ROS generation, demonstrated as enhancement of the red
fluorescent dots when compared with control rat aortas. Treat-
ment with the B1R antagonist reduced ROS generation in aortas
from ANG II-infused rats (Figure 2A). The HPLC analyses
demonstrated a higher EOH/DHE concentration in aortas of
the ANG II rats when compared with the control rats, and the
B1R antagonist treatment corrected that. In contrast, no alteration
in E/DHE generation has been observed among the groups
(Figure 2B). ERK1/2 phosphorylation was increased in aortas
from ANG II-infused rats when compared with control and ANG
II+DAL rat aortas (Figure 2C).Those data suggest that B1R
activation contributes to ANG II-AT1 signaling in the vascular
tissue.
Figure 1. B1 and AT1 receptors expression in aorta and aortic smooth muscle cells (VSMC) primary culture. Bar graph shows B1
receptor (B1R) [A] and AT1 receptor [B] mRNA levels in aortas from control, ANG II (400 ng/Kg/min), ANG II (400 ng/Kg/min) + DAL (350 ng/Kg/min)
and ANG II (400 ng/Kg/min) + LOS (10 mg/Kg/day) rats. The receptors mRNA expression was calculated from the cycle threshold (Ct) value using the
D2Ct method for quantification. Values were normalized against b-actin mRNA. Data represented mean6SEM; n = 5–7 for each group; *P,0.05 vs
control. [C] Bar graph shows the temporal effects of ANG II (100 nM, 0–24 h) on protein B1R expression in aortic VSMC. [D] Bar graph shows B1R
expression in aortic VSMC after stimulation with ANG II (100 nM, 2 h), in the presence or not of AT1 antagonist, losartan (LOS – 10 mM). B1R
expression was normalized against the housekeeping protein b-actin. Data are presented as mean6SEM of 4 experiments. *P,0.05 vs. control.
doi:10.1371/journal.pone.0111117.g001
Table 1. Temporal effect of angiotensin II (ANG II) infusion alone, or associated with des-Arg9-Leu8-bradykinin (DAL), or losartan
(LOS) on systolic arterial pressure and the effect of ANG II, ANG II+DAL and ANG II+LOS, 14 days of infusion on aorta morphology.
Control ANG II ANG II+DAL ANG II+LOS
Systolic arterial pressure (mmHg)
Days of infusion
0 11661.9 (11) 11661.5 (11) 11961.5 (10) 11762.4 (5)
7 11562.1 (11) 14862.6* (11) 15066.6* (10) 12468.2** (5)
14 11562.3 (11) 18465.9* (11) 18768.7* (10) 12564.3** (5)
Aorta
Wall thickness (mm) 10167.1 (7) 13269.1* (7) 11468.5 (7) 10866.7** (5)
CSA (mm2.1023) 451619 (7) 640636* (7) 556663 (7) 487657** (5)
W/L (1022) 6.560.2 (7) 7.660.4 (7) 6.660.4 (7) 6.560.4(5)
Systolic arterial pressure and thoracic aorta wall morphology. Systolic arterial pressure temporal evaluation in ANG II (400 ng/Kg/min), ANG II (400 ng/Kg/min)+DAL
(350 ng/Kg/min) and ANG II (400 ng/Kg/min)+LOS (10 mg/Kg/day, gavage) rats. Thoracic aorta wall morphology in control, ANG II (400 ng/Kg/min), ANG II (400 ng/Kg/
min)+DAL (350 ng/Kg/min) and ANG II (400 ng/Kg/min)+LOS (10 mg/Kg/day, gavage) rats. Aorta cross-sectional area (CSA), wall thickness and wall/lumen (W/L) ratio.
Data are represented as mean6SEM; (n) indicates the number of animals in each group *P,0.05 vs control; **P,0.05 vs ANG II.
doi:10.1371/journal.pone.0111117.t001
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ANG II and B1R agonist have synergistic effects on
NADPH oxidase-induced superoxide anion generation in
aortic VSMC
In order to determine if there is a synergistic effect between AT1
and B1 receptors signaling, primary cultures of aortic VSMC were
treated with ANG II and DABK in a low (0.1 nM) concentration.
At this concentration, neither ANG II or DABK alone induced
NADPH oxidase activation, but when applied together a
significant increase of NADPH oxidase-derived superoxide anion
generation was observed (Figure 3A). This effect was inhibited by
LOS and DAL, as well by Tiron, a superoxide anion scavenger
(Figure 3A). In the absence of DABK, a B1R agonist, ANG II at a
high concentration (100 nM) increased superoxide anion gener-
ation when compared with vehicle. This effect was inhibited by
LOS, but not by DAL, a B1R antagonist (Figure 3B).
ANG II and B1R agonist have synergistic effects on ERK1/
2 phosphorylation, protein synthesis and PCNA
expression in VSMC
ANG II and DABK at low concentration (0.1 nM) increased
ERK1/2 phosphorylation (Figure 4A) only when added together
and this effect was abolished by LOS, DAL and Tiron (Figure 4A
and B). On the other hand, at a high concentration (100 nM)
ANG II and DABK induced ERK1/2 phosphorylation when
applied alone and no additional effect was observed when the
peptides were applied simultaneously (Figure 4C).
PCNA expression and [H3] leucine incorporation were assessed
as molecular markers of cell growth. As demonstrated in
Figure 5A, ANG II and DABK at low concentration (0.1 nM),
increased PCNA expression only when added together and these
effects were abolished by LOS, DAL and Tiron. In the absence of
DABK, ANG II at high concentration (100 nM) increased PCNA
Figure 2. B1 receptor antagonism prevented angiotensin II (ANG II) effect in aorta. [A] Fluorescence microscopy of aortic transverse
sections after incubation with DHE. [B] Ratios of 2-hydroxyethidium/dihydroethidine (EOH/DHE) and ethidium/dihydroethidine (E/DHE) obtained by
HPLC analysis from aortic segments. Data are expressed as mean 6 SEM of 5 rats for each group. *P,0.05 vs control and **P,0.05 vs. ANG II [C] Bar
graph shows the ratio of phosphorylated/total ERK1/2 that was used as an indicator of ERK1/2 activity. Data are expressed as mean 6 SEM of 6 rats
for each group. *P,0.05 vs control and **P,0.05 vs. ANG II.
doi:10.1371/journal.pone.0111117.g002
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expression when compared with vehicle. This effect was not
changed by DAL, a B1R antagonist, but was inhibited by LOS,
AT1 receptor antagonist (Figure 5B). ANG II and DABK at low
concentration (0.1 nM) increased [H3] leucine incorporation only
when added together and LOS plus DAL abolished this effect.
ANG II at high concentration (100 nM) increased [H3] leucine
incorporation when compared with the control (vehicle) cells
(Figure 5C).
Discussion
Here we have demonstrated for the first time by in vivo and in
vitro studies that B1R is upregulated in hypertensive ANG II-
infused rats and contributes to vascular hypertrophy through a
redox-sensitive ERK1/2 pathway.
We previously demonstrated that ANG II has a modulatory
effect on B1R protein expression in the cardiovascular system
[11,12]. In addition, the increase in vascular B1R expression
induced by ANG II relies on AT1 receptor activation, superoxide
anion production by NADPH oxidase, PI3-kinase and NF-kB
activation [11,12,21]. ERK1/2 plays a role in NF-kB activation by
Figure 3. Effect of angiotensin II (ANG II) and des-Arg9-bradykinin (DABK) on superoxide anion generation in VSMC. [A] Bar graph
demonstrates the effects of ANG II (0.1 nM), DABK (0.1 nM) and ANG II-DABK co-stimulation for 5 min, in the presence of either vehicle, AT1
antagonist losartan (LOS – 10 mM), B1 receptor antagonist des-Arg9-Leu8-bradykinin (DAL – 10 mM) or superoxide anion scavenger (TIRON - 1 mM) on
superoxide anion generation. Results were expressed as mean6SEM of 5 experiments. *P,0.05 vs vehicle. [B] Bar graph demonstrates the effects of
ANG II (100 nM) stimulation for 5 min, in the presence of vehicle, AT1 antagonist, losartan (LOS – 10 mM), or B1 receptor antagonist, des-Arg9-Leu8-
bradykinin (DAL – 10 mM). Results are represented as mean 6 SEM of 5 experiments. *P,0.05 vs vehicle.
doi:10.1371/journal.pone.0111117.g003
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inflammatory stimulus that up regulates B1R [22]. However,
ERK1/2 does not seem to be involved in ANG II-induced B1R
up-regulation, since B1R antagonism reduced ERK1/2 activation
but did not interfere with aortic B1R expression.
ANG II plays an important role in the etiology of cardiovascular
diseases and also in the pathophysiology of cardiac and vascular
hypertrophy [23]. A growing body of evidence suggests that ANG
II effects on vascular structure are mediated by ROS production,
through NADPH oxidase, and MAPK activation, which can
mutually stimulate each other [24,25]. In this study, we show that
B1R activation, by endogenous DABK, contributes to vascular
hypertrophy in ANG II-induced hypertension, by a mechanism
involving ROS generation and ERK1/2 activation. In fact, it has
been reported in isolated VSMC that DABK increases ERK1/2
activation via a cholera toxin–sensitive pathway [7]. In addition,
kinins stimulate NADPH oxidase during inflammatory processes
Figure 4. Effects of des-Arg9-bradykinin (DABK) and angiotensin II (ANG II) on ERK1/2 activation. [A] Aortic VSMC from Wistar rats
treated with ANG II and/or DABK at low concentration (0.1 nM) in the presence of vehicle, losartan (LOS – 10 mM), des-arg9-leu8-bradykinin (DAL –
10 mM) and [B] TIRON (1 mM). Bar graph shows the ratio of phosphorylated/total ERK1/2 that was used as an indicator of ERK1/2 activity. Results are
represented as mean6SEM of 5 experiments. *P,0.05 vs Vehicle. [C] Aortic VSMC from Wistar rats were treated with ANG II and/or DABK at high
concentration (100 nM). Bar graph showed the ratio of phosphorylated/total ERK1/2 that was used as indicator of ERK1/2 activity. Results are
expressed as mean 6 SEM of 5 experiments. *P,0.05 vs vehicle.
doi:10.1371/journal.pone.0111117.g004
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[26]. Furthermore, ANG II and DABK interaction increased
PCNA expression and protein synthesis, supporting the hypothesis
that DABK/ANG II interaction contributes to VSMC hypertro-
phy.
Whether the role of B1R expression in the cardiovascular
system is beneficial or harmful remains inconclusive. After
myocardial infarction [6] and in diabetic nephropathy [27] kinin
receptors contribute to the protective effect of ACE inhibitors. On
the other hand, it has also been demonstrated that blocking or
deleting B1R protects the heart against injury and myocyte death
[28,29]. In agreement, we [30] and others [7] have demonstrated
that B1R activation is related with several intracellular signaling
pathways that have a key role in the development of vascular
damage. Altogether, at present, there is no good explanation for
the discrepancies described and investigations in different models
of cardiovascular disease are needed to clarify these issues.
Deletion of kinin receptors gene causes downregulation of ANG
II receptors [31]. Therefore, a decrease in vascular AT1R
expression may be involved in the anti-hypertrophic effects of
the B1R antagonist. However, our results do not support this
hypothesis, since B1R antagonist infusion for 14 days did not
interfere with AT1 receptor expression. It is important to note
that, although AT1 receptor expression was not changed either by
ANG II or B1R antagonist treatments, AT1 receptor activation is
necessary for DABK/ANG II interaction, since AT1 antagonism
in vivo prevented both the increased B1R expression and the
vascular hypertrophy. LOS also prevented the synergism between
low concentration of ANG II and DABK as well as the effects of
ANG II at a high concentration, confirming the participation of
AT1 receptors.
Synergistic interactions between kinins and ANG II receptors
have also been described in pathological conditions, such as
preeclampsia. In this condition, AT1 and kinin B2 receptors form
stable heterodimers, resulting in enhanced activation of down-
stream signaling pathways via the AT1 receptor [32,33]. Thus, it is
might be possible that ANG II and DABK interact in VSMC
through the formation of heterodimers between AT1 and B1Rs.
However, more studies are needed to clarify this issue. Since the
inhibition of vascular wall hypertrophy by B1R antagonism in vivo
occurred in the absence of changes in systolic arterial blood
pressure, we can conclude that AT1-B1R interaction is not
involved in the hypertensive effect of ANG II. In fact, it is known
that ANG II increases medial aortic VSMC via mechanisms that
are independent of increases in systolic arterial blood pressure [4].
This is consistent with our data from VSMC, where ANG II and
the B1R agonist increased PCNA expression and [H3] leucine
incorporation, used as markers of cell growth. This finding led us
to conclude that the effect of B1R antagonism on aorta
hypertrophy is independent of changes on blood pressure levels.
The role of B1R on blood pressure control is still controversial.
Whereas Martins et al. [34] reported that neither the B1R agonist
DABK or the B1R antagonist DAL injected into the fourth
ventricle modified blood pressure in spontaneously hypertensive
rat (SHR) or Wistar–Kyoto rats, other studies showed an effect of
B1R on blood pressure levels. In fact, centrally expressed B1R are
involved in the maintenance of high blood pressure levels in SHR
[35]. These authors showed that the B1R antagonist DAL injected
into the lateral ventricle (i.c.v.) reduced blood pressure levels in
SHR, but not in Wistar–Kyoto rat. Emanueli et al. [36] also
reported that i.c.v. activation of B1R in SHR and Wistar–Kyoto
rats evokes increases in blood pressure. Non-peptide kinin B1R
antagonists, LF22-0542 and SSR240612, decreased systolic blood
pressure in glucose-fed hypertensive rats [34,37]. The authors
suggested that the anti-hypertensive effect of these antagonists was
most likely centrally mediated since a peptide B1R antagonist,
which does not cross the blood–brain barrier, did not alter blood
pressure [34,37]. Since subcutaneous administration of the peptide
antagonist DAL did not interfere with the development of
hypertension, we suggest that peripherally expressed B1R might
not be involved in ANG II-induced hypertension. Moreover, the
physiological control of blood pressure does not appear to involve
B1R, since B1R knockout mice do not display a hypertensive
phenotype [38].
In summary, our data reveal a novel molecular mechanism
involving ANG II and DABK in vascular cells that may amplify
cellular responses. We show that ANG II and DABK, via AT1 and
B1 receptors, synergistically activate the redox-regulated ERK1/2,
which can regulate aortic VSMC growth in vivo and in vitro,
contributing to vascular remodeling in hypertension. Our findings
highlight an important cross-talk between the DABK and ANG II
in the vascular system. Also they contribute to a better
understanding of the mechanisms involved in hypertension-
associated vascular remodeling.
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